Heather A. Wakelee, MD, Stanford University, Stanford, CA, discusses non-small cell lung cancer (NSCLC) highlights from the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, including the results of a FDA analysis, looking across metastatic NSCLC trials of patients with 1-49% PD-L1 expression; chemotherapy and immunotherapy in combination was found to be more effective than immunotherapy alone. In addition, data was presented concerning EGFR TKI osimertinib in EGFR mutated NSCLC; results were consistent with previous research, with disease-free survival (DFS) benefit but no overall survival (OS) benefit. Future research may focus on determining the optimal strategy for early-stage patients, considering screening for salient biomarkers, such as EGFR and PD-L1. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Heather A. Wakelee, MD has received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, Sea Gen, Xcovery; is on the advisory board (compensated) of AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn; is on the advisory board (not compensated) of Merck Genentech/Roche; the president elect at IASLC; part of the executive committee at ECOG-ACRIN.